LAG3 and melanoma: Further clinical trials, such as the phase I trial (NCT04140500) investigating the effect of a bispecific anti-PD-1 and anti-LAG-3 antibody (RO7247669) on solid tumors, may validate the above conclusions and expand the treatment options for patients with melanoma [95,96].